NOVOS Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 32

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 24

NOVOS General Information

Description

Provider of healthcare drink supplement enriched with anti-aging and longevity qualities intended to improve mental health and wellness. The company's products include nicotinamide riboside, magnesium, fisetin, and pterostilbene, as well as antioxidants and other functional ingredients that improve DNA repair and reduce DNA damage, allowing consumers to expand their lifespan and improve their health.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 100 Park Avenue
  • 16th Floor
  • New York, NY 10017
  • United States
+1 (646)
Primary Industry
Pharmaceuticals
Other Industries
Other Consumer Non-Durables
Food Products
Corporate Office
  • 100 Park Avenue
  • 16th Floor
  • New York, NY 10017
  • United States
+1 (646)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NOVOS Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 05-Mar-2026 Completed Generating Revenue
1. Seed Round 01-Oct-2021 Completed Generating Revenue
To view NOVOS’s complete valuation and funding history, request access »

NOVOS Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed-2
Seed-1
To view NOVOS’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

NOVOS Patents

NOVOS Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026064455-A1 Senolytic compositions and uses thereof Pending 20-Sep-2024
EP-4518832-A1 Chondroitin- and collagen peptide-based methods for slowing down aging and extending lifespan Pending 06-May-2022
EP-4518832-A4 Chondroitin- and collagen peptide-based methods for slowing down aging and extending lifespan Pending 06-May-2022
US-20260248840-A1 Chondroitin- and collagen peptide-based methods for slowing down aging and extending lifespan Pending 06-May-2022
WO-2023215454-A1 Chondroitin- and collagen peptide-based methods for slowing down aging and extending lifespan Inactive 06-May-2022 A61K38/39
To view NOVOS’s complete patent history, request access »

NOVOS Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NOVOS Investors (24)

Investor Name Investor Type Holding Investor Since Participating Rounds
Unilever Ventures Corporate Venture Capital Minority
Angel (individual) Minority
Angel (individual) Minority
Arkitekt Ventures Venture Capital Minority
Asia Venture Group Venture Capital Minority
You’re viewing 5 of 24 investors. Get the full list »

NOVOS FAQs

  • When was NOVOS founded?

    NOVOS was founded in 2018.

  • Where is NOVOS headquartered?

    NOVOS is headquartered in New York, NY.

  • What is the size of NOVOS?

    NOVOS has 32 total employees.

  • What industry is NOVOS in?

    NOVOS’s primary industry is Pharmaceuticals.

  • Is NOVOS a private or public company?

    NOVOS is a Private company.

  • What is NOVOS’s current revenue?

    The current revenue for NOVOS is .

  • How much funding has NOVOS raised over time?

    NOVOS has raised $3.62M.

  • Who are NOVOS’s investors?

    Unilever Ventures, , , Arkitekt Ventures, and Asia Venture Group are 5 of 24 investors who have invested in NOVOS.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process